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Cell Migration, Chimerism, 
and Graft Acceptance: 
a New View of Organ Transplantation 
U. Cillo, A.J. Demetris, M. Trucco, N. Murase, C. Ricordl. T.E. Starzl 
Liver transplantation, as well as replacement ot 
Llther whole organs, whether abdominal or thoracic, 
has now reached a high level of technical and mana-
gement standardization. 
Indeed, organ replacement has become an indi-
..;pensable therapy for end-stage diseases of the liver, 
heart, kidneys and lungs. 
However, though important progress has been 
made in the control and prevention of organ rejec-
tion (especiallv after Cyclosporin A and FK506 were 
introduced into clinical practice). immunological 
phenomena such as acute and chronic rejection are 
still responsible tor a large percentage of post-
transpl,1l1t morbiditv and mortality. 
Further. we still know very little' about the mecha-
l1lsms Involved in the acceptance of whole grafts un-
der the LlsLlal immunosuppressive therapies availa-
ble todav. 
Starzl 'et ,11. have recently shown how the ex-
change of migratorv leukocv'tes between donor and 
reClp'ient Dlfte~ whole organ transplantation leads to a 
state of long-term cellular chimerism. This chime-
rism could be crucial to the acceptance of all whole 
prgan allografts and xenografts. 
\ Ve believe this hypothesis radically changes the 
wav we should look at whole organ transplants. in-
deed, it is a speculation that on one hand enables us 
to deepen our understanding of transplantation im-
munology, and on the other hand it opens up the 
field for the development of new therapeutic strate-
pes. 
THE MICROCHIMERISM CONCEPT 
Successful organ transplants were for a long time 
considered as compact alien gratts in a compact and 
homogeneous recipient organism. The first doubts 
about this viewpoint were expressed in 1969 by KA 
Porter, who used karyotyping techniques to study 
female recipients ot livers obtained from male cada-
veric donors . 
Porter showed that, following transplantation, the 
entire hepatic macrophage system, including the 
Kupffer cells, was replaced by female recipient cells 
within 100 days after the transplant [1, 2]. 
This was the first unequivocal evidence that who-
le-organ grafts in humans become genetic composi-
tes and that a state of chimerism is created after tran-
splantation. 
LOCAL MICROCHIMERISM 
Even though from the 1970s onward a number of 
clinical reports have suggested the presence of local 
chimerism in long surviving human renal allografts 
[3-5] or in subhuman primates [6], the chimerical 
structure of the hepatic graft was for many years 
considered an exception within the context of who-
le-organ transplantation. 
In 1991 it was shown, first on animal models [7] 
and then on humans, that also after small bowel 
transplantation the graft lymphoreticular system 
(lymphoid, dendritic and other leukocytes in the la-
mina propria, Peyer's patches and mesenteric nodes) 
is completely replaced by cells that are smtilar but 
belong to the recipient. 
These findings led to the innovative hypothesis 
that graft chimerism might be a generiC feature of all 
accepted grafts. 
Further studies provided <1m pie evidence of the 
existence of graft chimerism <liter transplantation 
of kidnevs [8, 9] and thoracic organs as well [10-
12]. . 
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SYSTEMIC MICROCHIMERISM 
The discovery that local microchimerism occurred 
in all kinds of whole organ grafts brought up the old 
question of what happened to the donor cells that 
had disappeared from the graft. The importance of 
this question had been largely underestimated. 
Since the discovery of chimerism in the transplan-
ted liver, it had been assumed that the cells depar-
ting from the graft were quickly destroyed. This con-
viction was firmly rooted in spite of circumstantial 
evidence indicating that donor cells migrating from 
the engrafted organ will survive in the recipient or-
ganism. 
In the case of kidney transplantation, for example, 
skin test studies (tubercolin, histoplasmin, blastomy-
cin, coccidiodin, mumps, Calldida and Trichophyton) 
on kidney donors and recipients in the early 60s 
(Starzl's early Colorado Kidney Transplant) (13] pro-
vided indirect evidence of the existence of svstemic 
chimerism, though this interpretation was not consi-
dered plausible at the time. 
Seventy-seven percent of the negative skin test pa-
tients who received kidnevs from positive skin test 
donors became positive after transplantation. The re-
maining 23%, in whom the skin tests did not change 
to positive after transplantation, coincided with tran-
splant failure. The authors of the study speculated 
that the secondary acquisition of the positive skin 
tests was "caused by adoptive transfer of donor cel-
lular immunity by leukocytes in the renal graft va-
sculature and hilar lymphoid tissue" [13]. At the ti-
me, however, the possibility of cells migrating from 
the kidney graft to the recipient organism was consi-
dered untenable because the kidney was then 
thought to be a "leukocyte-poor" organ. 
[n the case of liver transplantation, the discovery 
that new donor-specific immunoglobulin (Gm) types 
.lppeared and were maintained in the blood of liver 
transplant recipients [2, IS] could have suggested, as 
t.1[ back as [969, that donor cells departing from the 
graft remained vital in the reCipient organism even 
for long periods after transplantation and were re-
sponsible for immunoglobulin production. 
Similarly, the demonstration of the presence of so-
luble HLA antigens (Class I) in the circulation of li-
ver graft reCipients [16] was basically misinterpreted. 
It was considered, in fact, to be of hepatocytic origin, 
.llthough we now know that these molecules are 
produced by histiocytes or dendritic cells, both of 
medullary origin. 
Ramsey proposed in 1984 that cells migrating from 
the graft might be responsible for the production of 
.lOti-red blood cell antibodies encountered in reci-
pients of ABO-unmatched livers [171. 
This, as well as the other indirect evidence of sv-
stemic microchimerism, was unfortunately ignored 
at that time and correctly interpreted only later. 
Direct evidence of svstemic chimerism was on[v 
l)btained in 1991, when'Murase et al. used flow cvto-
metry to demonstrate that, after intestinal transpiant 
in rats treated with FK506, the stromal leukocvtes 
leaving the graft then distributed themselves in l.iuge 
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numbers. throughout the recipient'S entire lymphoid 
tissue [18-20]. This cellular migration led to a state of 
systemic mixed allogenic chimerism lasting at least 
45 days after the transplant. Interestingly, this condi-
tion of systemic chimerism did not lead, except in 
certain special strain combinations, to any signs of 
graft-versus-host disease (18-20]. Due to the time li-
mit of the above mentioned experimental model (45 
days), the long-term destiny of cells migrating to the 
recipient tissues was unclear throughout 1991. This 
experience served as the stimulus for definitive stu-
dies over the follOwing months on long-term syste-
mic chimerism in human recipients of kidneys, liver 
and other organs. 
From April to July, 1992, direct evidence of syste-
mic chimerism was sought both in kidney or liver 
transplant patients with a long term survival after 
successful transplant. 
These studies were based on the distinctive featu-
res of two chromosomes, the sex chromosome Y and 
chromosome 6, in recipient and donor. On the one 
hand, cells with the Y chromosome were sought in 
the tissues and blood of females who had received 
the organ from a male donor, and on the other, cells 
with HLA alleles of chromosome 6 belonging to the 
donor were sought in the tissues ot the recipient. 
Two techniques were used in the study on chromo-
somes Y and 6: cytostaining (which makes location 
and morphological characterization of phenotypical-
ly distinct donor and recipient cells possible) and po-
lymerase chain reaction (PCR), which distinguishes 
the donor's DNA from that of the recipient [8, 21-25]. 
These techniques were applied to tissue biopsies 
obtained from a group of 5 living related kidnev 
transplant recipients with graft survival from 27 to 
29 years [26]. Some of these patients had taken part 
in skin test studies almost 30 vears before. One of 
the five patients had suspended all immunosuppres-
sive therapy and the other four were still taking aza-
thioprine with or without steroids. 
All five patients had received HLA-incompatible 
kidneys, so it was possible to distinguish between 
donor ,md reCipient cells. In two cases, the donors 
were of the opposite sex. 
Cytochemical analysis and peR studies on graft 
biopsies demonstrated in all five cases that the inter-
stitialleukocyte population was widely represented 
by the recipient's cells, whereas the nephrons remai-
ned genotypicaIly the donor's. More importantlv, in 
all five cases, skin and lymphonodal biopsies revea-
led the presence of the donor's cells (apparently 
dendritic leukocytes), demonstrating for the first ti-
me in a human being the presence of low-level syste-
mic chimerism (microchimerism) in the host tissues 
almost 30 years after the transplant took place. 
The fact that four of the five volunteer kidnev do-
nors were still alive also made it possible to demon-
strate donor-spedfic non-reactivity by means of mi-
xed lymphocyte reactivity (MLR) and/or cell media-
ted lymphocytotoxocity (CML) testing. 
A similar study was also performed on a group of 
25 liver redpients with gratts functioning well 2 to 22 
after the transplant [25]. 
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Analysis using cytochemical or peR techniques on 
skin, lymph nodes, heart, lungs, spleen, intestine, 
kidneys, bone marrow and thymus demonstrated 
the presence of donor cells (systemic chirrierism) in 
all 25 recipients. Interestingly, the number of chime-
ric cells found in the host organism after liver tran-
splant was higher than that observed in long survi-
ving kidney recipients. 
Subsequent studies by A.J. Demetris et al. on liver 
transplant models in rats gave evidence that passen-
ger leukocytes of the hepatic graft spread through 
the recipient's lymph nodes, spleen and thymus wi-
thin a few hours after the transplant, without this 
migration being conditioned by the presence or ab-
sence of immunosuppressive therapy. However, the-
se cells disappeared completely within the space of 
several davs in non treated animals, whereas in rats 
given a brief course of FK506 (2 weeks), these pas-
senger leukocytes survived, leading to a permanent 
state of low-level chimerism associated with indefi-
nite liver graft survival [14, 27J. 
FUNCTIONAL CONSEQUENCES 
OF MICROCHIMERISM 
The proof of the existence of a mixed chimeric sta-
te after whole organ transplants leads to the impor-
tant question of what the functional significance of 
immunocompetent recipient and donor cells coexi-
sting in the same organism might be. The relatively 
low number of cells from the donor in the recipient's 
tissues. even after transplant of a leukocyte-rich or-
gan like the liver, could cause some doubt as to the 
,Ictual functional importance of chimerism. 
fhe vlrtuallv ubiquitous distribution of chimerism, 
however. suggests that the cumulative effect of do-
nor cells, and consequently their functional impor-
tance, is considerable. There IS also considerable eVI-
dence to indicate how important the role of these 
cells is. particularly after liver transplantation, where 
it is most easilv demonstrated. 
METABOLIC EFFECTS 
The capacitv of the chimeric cell population to ha-
ve important metabolic effects was demonstrated in 
patients undergOing liver transplantation for type 4 
glycogen storage disease (branching enzyme defi-
ciency with amylopectin storage) and Gaucher's di-
sease (B-glucocerebrosidase deficiency and storage 
llf glucocerebrosides) (23). Although it was thought 
that only a bone marrow transplant could be used to 
treat such disorders (since the enzvmatic deficiencv 
involves all cells), surprisingly, 2-8 years after liver 
transplant, complete resorption of the storage mate-
rial in the recipient's tissues was witnessed. 
Chimenc cells from the donor found in all the reci-
pient's tissues had caused resorption of the storage 
material, probably via a co-culture effect on the en-
zyme-deficient recipient cells (present in a much hi-
gher number). 
These observations lead to the hypothesis that a 
similar cellular interaction mav also occur in the mo-
re complex immunological processes. 
IMMUNOLOGICAL INTERACTION 
The question remains as to what mechanism al-
lows systemic chimerism to persist for such a long ti-
me after transplantation. It is likelv that a certain 
number of tissue leukocytes present in the tran-
splanted organ do not reach complete differentia-
tion, as was once believed, but retain the capacity to 
migrate and proliferate. 
Under immunosuppressive therapy these pluripo-
tent, progenitor cells present in the interstitium of 
the graft give rise to immunocompetent cell lineages 
(dendritic cells and other leukocytes), which replica-
te indefinitely in the recipient's tissues. 
lnaba et al. recently demonstrated the possibility 
of generating a large number of dendritic cells from 
precursors grown from mouse bone marrow cultu-
res. blood or whole organs supplemented with GM-
CSF [28J. How and under what stimulus the conti-
nued proliferation of these cells occurs ill vivo is not 
clear. Starzl et ai. suggested that chronic mutual sti-
mulation of the donor and recipient cell populations 
might occur after the transplant [24. 27J. In this con-
text, as noted by Bandeira et al.. the tolerogenicity 
arising from such an interaction shares many of the 
characteristics associated with immunitv [29]. 
According to this hvpothesis, the two coexisting 
immunocyte populations interact reSUlting in a state 
of immunologic balance. This balance is thus the re-
sult of a "mutual natural immunosuppression". 
The very existence of this persistent cellular inte-
raction depends on the permissive role played by the 
immunosuppressant drugs, which allow long-term 
microchimerism to establish itself once the mutual 
host-graft leukocyte migration has taken place. 
The development of this non-responsiveness re-
quires bidirectional alloachvation of a host-versus-
graft reaction (HVG - i.e. rejection) as well as graft-
versus-host activity (GVH), causing reciprocal and 
persistent stimulation of the two immune systems 
(Fig. 25.1). Alterations in this state of dynamic equili-
brium can therefore result in either rejection or a 
GVHD. In successful cases of organ transplantation, 
however, this cellular interaction between the donor 
and the reCipient under immunosuppressive thera-
py can drastically reduce the danger of a host-
versus-graft reaction as well as rejection. 
In particular, this mutual natural immunosuppres-
sion is effective even in the case of organs with poor 
Iymphoreticular consistency, like the kidneys or 
heart. 
Similarly, this mutual immunolOgiC stimulation is 
responSIble for the well-known resistance to GVHD 
of leukocyte-rich organs such as the liver, small bo-
2S8 
GVH 
Mutual Natural 
Immunosuppression 
~ 
HVG (Rejection) 
wei or combinations of intra-abdominal organs (mul-
tivisceral transplantation) [30]. 
It was known as far back as the 70s that a GYHD 
can be avoided in mice even after bone marrow tran-
~plantation if the recipient immune system is main-
tained intact [31]. Some \'ears later Ildstad and Sachs 
validated these studies 'bv producing various mix-
tures of donor and recipient bone marrow cells ex pi-
,'0 and then creating mixed allogeneic chimeras by 
infusing the mixtures into c~ .. toablated recipients 
who ~ilbsequently did not develop GYHD [32]. 
These studies experimentallv recreated what oc-
curs in clinical practice when treating recipients of 
whole organ transplantations WIth immunosuppres-
~antsK fhe key to the success obtained empirically in 
,1 clinical setting lies in permitting the interaction 
between the two cell populations and in the need to 
,lVoid altering this interactIon by ablatIng or weake-
ning one of the two populations in favour of the 
l)ther. It therefore becomes essential to avoid com-
~1romising recipient reactivity with pretreatments or 
Impoverishing the immunological component of the 
graft. 
Since both cell groups receive the same protectIve 
immunosuppression, the more successfully the 
equilibrium between the two cell populations is 
maintained, the more reasonable it is to expect resi-
stance to GYHD or to rejection. 
MUTUAL CELL ENGAGEMENT 
AND TISSUE MATCHING 
Also the limited correlation between HLA matching 
and outcome in whole organ cadavenc transplanta-
tion (33-35] finds a rational interpretation in the pre-
sence of a mIxed long-tenn chimerism (8, 21, 25]. 
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Fig. 25.1. The mutual engage-
ment of migratory leukocytes 
from the graft and the recipient 
under potent pharmacologic im-
munosuppression. 
GVH: Graft-versus-host: 
HVG: Host-versus-graft. 
(Modified from [25]). 
Interaction between donor and reCIpient coexi-
sting leukocytes intensifies the higher the degree of 
histoincompatibility, reaching progressively higher 
grades of mutually cancelling donor-vs-recipient 
and recipient-vs-donor reactivity (Fig. 25.2). 
o~ 
Match 
Gr.ft ~ Host 
em & wm 
Mutual 
Natural , 
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Total 
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Fig. 25.2. The donor·reclplent leukocyte mteraction is a sort 
of buffer against GVHD on one hand and HVG reaction on the 
other. l4!to and suppressor cells are suggested to be the re-
sult of the interaction. 
RX ImmunosuppreSSIve therapy, 
(Modified from [25]). 
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The permissive action of current immunosuppres-
sants allows mutual cell engagement between the 
two systems to occur and a condition of rapproche-
ment to be reached. In the case of liver transplant, 
this vindicates the two reports from Cambridge [36] 
and Pittsburgh [37] which produced evidence of an 
inverse relationship between tissue matching and 
survival of recipients. It also becomes easy to under-
stand how even in the case of six-antigen-matched 
cadaver kidney allografts, the clinical advantage is 
minimal compared with kidney transplants with a 
lesser degree of matching. 
THE DENDRITIC LINEAGE 
The most prominent chimeric cell by morphologi-
cal criteria is the dendritic cell [8, 21-25, 27]. It seems 
likely that this type of leukocyte plays a crucial role 
in determining the tolerogenic action of chimerism 
,1tter whole organ transplantation. 
In c1 normal immune response (whether rejection 
or GVHD), the efficient response of T cells to a given 
antigen requires professional antigen presenting 
cells (APCs) to correctly present the antigen to the T 
cell. To activate an effective immune response, it is 
then essential for the T cell to receive a co-stimulato-
ry signal from the APCs themselves [38J. 
Among these APCs, dendritic cells [39-41J are pro-
bably the most important in the context of chimeric 
interaction, since they can modify the expression of 
cell interaction, MCH and adhesion molecules, the-
rebv determining the way in which the antigen si-
gnals are heeded by the T cells [421. 
Obviously, other lineages can also be decisive in 
these complex immunological interactions. 
CELL MIGRATION AND TOLERANCE 
Although a discussion of the concept of tolerance 
is not our purpose here, it is important to define the 
relationship between cell migration and tolerogenici-
t\'. Several authors recentlv stated that thymic clonal 
deletion is inadequate as c1n explanation l)f acquired 
transplantation tolerance [431. 
The presence of a long-term microchimerism after 
whole organ transplantation, on the other hand, cmd 
the consequent, persistent interaction between the 
donor and the recipient immune system could well 
be consistent with and lend further weight to certain 
tolerance theories, such as peripheral (non-thymic) 
clonal deletion and anergy. 
Coutinho and Cohen have defined the acquired 
tolerance as a high (not anergic) level of sustained 
immune activity in immunological networks [29, 44, 
451. This immunological interaction is probably more 
complex than that of the idiotype system originally 
postulated by Jerne [46J. 
The cell migration-chimerism concept can therefo-
re be seen as a mechanism which uniformly explains 
achievement of donor specific non-reactivity, inde-
pendently of the characteristics of the immunosup-
pressant used or, in certain animal models, without 
any immunosuppression at all. The problem remains 
of identifying the finer mechanisms of microchime-
rism tolerogenicity. 
It would be interesting, for example, to under-
stand the relationship between drug-induced tole-
rance and the kind of acquired tolerance produced 
with intrauterine or neonatal splenocyte inoculation 
in the mice models of Billingham, Brent and Meda-
war [47]. 
On the basis of studies in drug-free models of tole-
rance induction, the theory has been put forward 
that T-cell receptor (TCR) occupancy can lead to the 
production of negative regulators of IL-2 production, 
the so-called anergy proteins [38, 48J. These negative 
regulators are inefficient during a normal immune 
response because they are diluted out by the vigo-
rous cell replication driven by IL-2. However, if clo-
nal expansion is inhibited by immunosuppressive 
drugs (lL-2 inhibitors or synthesis inhibitors) or bv 
the absence of a co-stimulatory signal (in drug free 
models) [38J, these negative regulators accumulate, 
leading to a state of anergy. 
The use of non T cell depleting monoclonal antibo-
dies or monoclonal antibodies against adhesion mole-
cules (ICAM-I, LFA-l) can also be envisaged [49J. 
As suggested by Coutinho [44J, it has been postu-
lated that in fullv successful cases, there has been 
complete integrafion of the donor's immunocompe-
tent elements into the existing recipient immunolo-
gical network [24, 27J, 
HEPATIC TOLEROGENICITY 
According to Starzl et aI., cell migration and repo-
pulation represent the basis for all whole organ graft 
cl(ceptance. 
However, not all organs carry the same density of 
immunocompetent cells potentic111~D capable of inte-
racting with the host immune system (Fig. 25.3). 
The abundance of leukocyte lineages, including 
Kupffer cells, in the liver is a particularly striking fea-
ture of this organ, with important implications for 
these cells in determining hepatic tolerogenicity. 
Among the various .1spects of the liver's "immu-
nological c1dvantages", the possibility of obtaining li-
ver allograft or xenograft acceptance after a limited 
course of immunosuppression [26, 50-52J or even 
with no treatment .ll all (some rat strain combina-
tions, swine) [53-571 is well known. The liver can al-
so induce a state of unresponsiveness to donor tis-
sues in the recipient. Its tolerogenic Jction does in 
fact Jssist .1cceptance of other organs .md tissues 
transplanted either simultaneously or subsequently 
from the same donor. 
The liver is also characteristicallv more resistant to 
the preformed antigraft antibodies .• md theretore to 
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Fig. 25.3. The explanation for the variable ability to induce 
acceptance and ultimately tolerance of different organs. 
The tissue content of potentially migratory cells is liver > in-
testine > lung> kidney> heart. 
(Modified from [25]). 
acute rejection, than organs such as the kidneys and 
heart. Its ability even to shield other organs against 
preformed allospecific [58] or xenospecific [59] anti-
donor antibodies which cause hyperacute rejection 
is also documented. 
According to the theory put forward by Starzl, 
these immunological characteristics of the liver graft 
are explained by its heavy endowment of migratory 
leukocyte lineages. In other words, the difference in 
terms of tolerogenicity between the various organ 
grafts depends on the extent of the leukocytic com-
ponent of each type of organ and certainly not on its 
parench ymal characteristics. 
In this context, the liver comes top of the list for 
"tolerogenic potential", followed by the intestine 
,lOd the lungs, with the kidneys and heart bringing 
up the rear (Fig. 25.3). 
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Various experimental studies on the tolerogenicity 
of the spleen [60-62], intestine [7] and lungs [63-64] 
concur with this conclusion. 
TOLEROGENICI1Y OF LEUKOCYTE "POOR" ORGANS 
Although easier to demonstrate in leukocyte-rich 
organ grafts like the liver and intestine, potential to-
lerance processes also occur in organs with a deci-
dedly lower leukocyte content, like the heart or kid-
neys, as demonstrated in 1992 [7, 18, 19, 65]. 
A wide range of studies has been performed on 
these organs in the past, but these concentrated on 
analYSis of alloactivation and rejection rather than 
tolerization. 
It was demonstrated, for example, that the allo-
reaction in untreated animals starts peripherally in 
the graft and centrally in the recipient lymphoid tis-
sues. 
Extensive leukocyte migration after rat kidney 
transplantation in non-immunosuppressed animals 
had already been demonstrated in 1981 [66]. Larsen 
et al. had also demonstrated that, after a heterotopic 
heart transplant, the donor's dendritic cells are relea-
sed into circulation and eventually home into the re-
cipient spleen [68]. -
At a splenic level, certain authors [66-70] believe 
that the donor cells stimulate proliferation of the re-
cipient's and vice versa, in what could appear to be 
an ill ('im mixed lymphocyte response (MLR). This 
reaction seems to epitomize central allosensitization 
with tolerization. 
It is likely that the processes of allosensitization 
(and tolerization) that occur centrallv also occur at 
graft level. . 
Havrv and Willebrand showed that in human reci-
pients of kidney grafts treated with Cyclosporine 
and steroids, needle aspiration biopSies appeared to 
indicate a bidirectional MLR [71, 72]. 
These and numerous other studies suggest that 
the differences with respect to leukocyte-rich organ 
transplantation seem to be quantitative rather than 
qualitative. Basically, the lower the number of migra-
tory leukocytes involved, the higher is the tendency 
for allosensitization rather than tolerance. Despite 
this, it has been demonstrated that after mouse heart 
and kidney transplantation between weakly MHC 
compatible strains in untreated animals, a condition 
of tolerance can occur [73, 74]. 
UNSTABLE MIXED CHIMERISM 
The chimerism concept, therefore, closely inter-
relates tolerance, rejection and GVHD. This fact reu-
nites the two disparate and far apart worlds of bone 
marrow transplantation and whole organ transplan-
tation into a single and relatively homogeneous fra-
mework. 
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Until very recently, this clear-cut distinction bet-
ween the two fields was in all probability the ex-
pression of two conflicting treatment dogmas (Fig. 
25.4). 
In the case of bone marrow transplantation, the 
conventional treatment requires optimal HLA mat-
ching. Recipient cytoablation, in fact, by preventing 
the establishment of cellular interaction between the 
donor and recipient immune systems tips the balan-
ce substantially in favour of the donor, which causes 
a GVHD in the event of an HLA mismatch. 
The immunosuppressive treatment adopted after 
whole organ transplantation, on the other hand, per-
mits mutual cell engagement and the establishment 
of a certain balance that drasticallv reduces the im-
portance of HLA matching. ' 
The aim in both whole organ transplantation and 
bone marrow transplantation is to avoid upsetting 
this interactive balance between the two immune sv-
stems, either in favour of the donor or recipient, thus 
preventing rejection or GVHD (Fig. 25.1). 
Examples of failure to reach this immunological 
balance are well described in the classic studies of in-
testinal transplantation between certain rat strain 
combinations involving the Brown Norway (BN) 
strain [18, 20]. 
ACI, PUG or LEW rats that underwent intestinal 
transplantation from fully allogeneic donors and we-
re given a daily course of FKS06 for 14 days and then 
weeklv did not develop either rejection or fatal 
GVHD. When, on the other hand, ACI intestine 
grafts were transplanted in BN rats, severe rejection 
occurred. Further, the combination of LEW or PUG 
donors to BN recipients proved vulnerable to GVHD 
after completion of the daily course. 
Solid Organ 
In all the strain combinations, however, it was 
possible to detect bidirectional cell traffic, with leu-
cocyte migration from donor to recipient and vice 
versa [18, 19]. The same tendency to rejection or 
GVHD under Cyclosporin was described in the case 
of WAG-BN strain combinations, with WAG as donor 
and BN as recipient [75]. 
It is still not clear to us why BN rats are "excellent 
donors" but "poor recipients". 
The problem implicit in these observations is how to 
recognize and identify in a clinical context the more fa-
vourable donor-recipient combinations and thereby 
avoid the more difficult ones, such as, in the case of rat 
experiments, LEW, ACI or PUG to BN combinations. 
In clinical experience, as in these experimental 
models, the signs of an unstable mixed chimerism 
are often verv clear. 
Although rejection is the major deterrent after li-
ver transplantation in humans, the incidence of clini-
cally significant GVHD accounts for around 5% of 
all cases in the early post-operative period. This di-
sorder is characterized, symptomatologically, by der-
matitis (often attributed in the past to drugs or aller-
gy) [25J, which can become serious and sometimes 
even fatal. 
These patients can be treated effectively by increa-
sing immunosuppression (especially the steroid do-
se) or more rarely, on the other hand, reducing im-
munosuppression. However, the presence of wide-
spread skin disorder, gastrointestinal symptoms and 
a reduction in blood crasis are correlated with a high 
mortalitv rate [76]. 
[ntere'stingly, it has been documented that in the-
se patients chimerism is more extensive than in pa-
tients whose course presented no complications. 
Gratt Take 
GVHD 
Fig. 25.4. The division of transplantation into two separate disciplines by divergent therapeutic dogmas. Therapeutic policies 
used in bone marrow transplantation precluded bidirectional cell migration. This phenomenon. on the contrary. was the funda· 
mental basiS for graft acceptance WIth the policies used in whole organ transplantation. 
(Modified from (251). 
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A good example of the consequences of an unba-
lancing of the donor-recipient interface is provided 
by the case of a 56-year-old patient with gastric leio-
mvosarcoma and liver metastases, who was tran-
splanted after an upper abdominal exenteration [77]. 
Just before the operation the patient had undergone 
total lymphoid irradiation (TLI) (single 550 rads dose 
thoraco-abdominal irradiation) and then infusion of 
19 x 1l~ of non-purged bone marrow cells. After a 
few weeks the patient experienced a serious GVHD 
with a > 80% skin involvement. The situation was 
not mitigated by either increasing or reducing the 
immunosuppression treatment. After about a month 
and a half from the transplant he was given an intra-
venous infusion of 1.23 x lOS and 1.6x 108 autologous 
unpurged bone marrow cellslkg (collected and sto-
red prior to TLl). The GVHD dramatically resolved 
over the next two weeks and the skin rash cleared 
up completely. Interestingly, now cytometry analysis 
of the donor and recipient circulating cells showed a 
25 to 3/);, reduction of mixed lineage donor cells in 
the blood coincident with resolution of the GVHD. 
Two important lessons were learned from this si-
gnificant clinical experience. The first is the unfavou-
rable effect of pre-operative TLl. Instead of "making 
space" for the new marrow cells, it risks upsetting 
the donor-recipient balance in favour of the donor, 
thereby causing a GVHD. The second is the poten-
tial value of native autologous bone marrow collec-
ted and stored before transplantation. This can be a 
lIseful treatment in the event of .111 unbalancing of 
the donor-recipient interface leading to GVHD. 
The capacitv of autologous marrow cells to block 
,1l1d resolve a GVHD sheds light, indirectly, on what 
happens during the mutual cellular interactions in 
mixed chimerism . 
. Although the number of bone marrow cells used 
to treat tile C\,HD mav be considerablv lower th,ln 
those In the patient's blood, their therapeutic value 
is probablv due to the fact that they ,He not prevlOu-
slv exposed to the donor marrow. These "\'irgin reci-
pient bone marrow cells" may be able to restore the 
immunological balance because they are not pre-
\'iouslv conditioned by the mutual cell engagement 
processes. 
CLINICAL TRIALS 
DRUG WEANING EXPERIENCE 
On the baSIS of the hypothesis outlined in this 
chapter, the llnmunologic advantages of liver tran-
splantation are related, as alreadv mentioned, to the 
llrgan's abundance of migratory leukocytes. Similar-
ly, the smaller tolerogenic potential of organs such as 
the kidney .1I1d heart may be explained by their 
smaller leukocyte component. 
The existence of a bodvwide mutual cell engage-
ment and the consequent development of a donor 
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and recipient specific non-reactivity after whole or-
gan transplantation is perfectly consistent with the 
fact that some patients can reach immunolOgiC tole-
rance and a drug-free state. 
The liver graft is obviously the organ most likely to 
be accepted in a drug-free condition on account of 
its considerable migratory cell constituency. 
In a recently reported group of 44 human liver re-
cipients who had survived 11-23 years after tran-
splantation, 14% had suspended "all immunosup-
pression 1 to 11 years post-operatively. These pa-
tients are clinically stable at the present time, with 
drug-free intervals from 5 to 13 years. Another 15 ca-
ses are showing no significant clinical result after in-
terrupting immunosuppression, albeit with a shorter 
follow-up [25, 78]. 
The earliest suspension of therapy in this study is 
a liver recipient who came off immunosuppression 
at 6 months after transplant, with a follow-up of 3 
years. 
" A trial of drug weaning has been started in Pitt-
sburgh in patients with a rejection free course ex-
ceeding 5 years. The benefits of coming off drugs 
make the risk of rejection acceptable now that it can 
be treated so effectively with drugs like FK506 [79]. 
However, it is very difficult to decide when to su-
spend immunosuppression, since we have no way 
of knowing when a potential drug-free state ha's 
been reached. 
This drug weaning experience in liver transplant 
recipients might be extremely useful for future clini-
cal trials of drug weaning after transplantation ot the 
heart or kidney, whose tolerogenicitv can be appro-
ximated to that of liver by using bone marrow aug-
mentation (see below). 
BONE MARROW AUGMENTATION 
The growing conviction that mixed cell chimensm 
is a crucial event in whole organ transplantation and 
in the subsequent induction of donor specific non-
reactivity has posed the problem of how to augment 
this natural phenomenon. 
Since the migratory interstitial cells are of hemato-
lymphoid origin, the next logical step was to aug-
ment the immunocompetent component by peri ope-
rative exogenous administration ot bone marrow. 
These considerations, and the clinical efficacy ot au-
tologous bone marrow cells in the treatment ot 
GVHD in the case described above, have led to fur-
ther attempts to use bone marrow augmentation to 
induce tolerance in whole organ recipients. 
In the past, various advanced strategies teatured 
intravenous infusion of donor marrow cells, spleno-
cytes or donor specific transfusion at the same time 
as transplantation or shortly atter. Such strategies 
are merely an augmentation of the normal post-
transplant cell migration [31, 32, 80-82J. To reprodu-
(e the natural process as far as possible, however, 
these cells should be administered perioperativelv, 
which is different from the so-called Monaco model. 
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Since December 1992, a clinical studY has been 
running at the University of Pittsburgh' on 16 reci-
pients of various organs aimed at inducing a higher 
level of chimerism by infusing bone marrow cells 
from the donor at the time of whole organ transplan-
tatio~ (such a trial is still underway in Pittsburg and 
now mcludes nearly 30 patients) [83]. 
The clinical purpose of this study was to eliminate 
or at least reduce the need for chronic non-specific 
immunosuppression. Table 25.1 lists the relevant da-
ta for the study population. No irradiation or any 
other cytoablative conditioning was used. 
The donor marrow was harvested from vertebral 
bodies and 3x 1M~ of untreated bone marrow cells 
were infused intravenous Iv immediatelv after the 
transplant. In all cases FK506 and steroids were 
used. The pancreatic islets were infused into the 3 
diabetic patients intraportally at the same time as the 
bone marrow infusion. 
All the patients and their grafts are doing well at 
the present time (follow-up of 3 to more than 13 
months). 
Some of these patients, however, showed (as ex-
pected) host-versus-graft (HYG) and graft-versus-
host (GYH) reactions. In particular, 11 of the 16 pa-
tients developed mild to moderate acute cellular re-
jection over the first month .md a half after tran-
splant (Tab. 25.2). In all cases rejection was succes-
sfull~D treated simply by increasing the dose of routi-
ne immunosuppressant drugs, with one exception 
(heart transplant) which required an additional cour-
se of OKT3 therapy. 
Two liver transplant patients, on the other hand. 
showed signs of GYH reaction characterized bv skin 
rash without other organs being involved. These 
s\,mptoms disappeared completelv within 3 weeks. 
Steroids had to be increased in I 'case onlv. 
Chimerism analysis in the recipients was perfor-
med by immunocytochemical staining of recipient 
peripheral blood lymphocytes (PBl) using donor 
.1I1d recipient-specific anti MHC class I monoclonal 
.lI1tIbodies (mAb). 
Chimerism was also assessed bv flow cvtometrv 
.md by PCR using donor and rec(pient specific DR 
probes. Fifteen of the 16 patients h.we demonstrable 
macrochimerism, the only exception being a kidney 
reCipient with a perfect MHC match from a donor of 
the same sex who had no markers to be studied, the 
LIse of different technologies allowed cross-confir-
mation of results. The highest yield was with PCR, 
showing chimerism in 1-1 of the 16 C,lses. After male 
to temale transplantation in -l cases, all -l recipients 
h.1d Y chromosomes detectable, and in these cases 
there was an excellent correlation with the results 
llbtained using HLA alleles. The vield with t10w cv-
tometry was 13/16. showing 0.6 to R°~I circulating do-
Ilor leukocytes 50 days to 1 year after transplanta-
tion. In the control group, on the other hand, the do-
Ilor cells were ,1lmost undetectable -l weeks after 
transplantation (Tab. 25.3). Furthermore, ,1Oalvsis bv 
tlow cytometry and immunotluorescent labeiling of 
E~·tospins succeeded in showing multiple lineages of 
donor cells (T cells, B cell, NK cells. M0 and CD33+/ 
Table 25.1. Transplant groups. 
Controls Study group OrganTx (Allografts alone) (Bone marrow + 
solid organ) 
Liver 4 5 
Liver + Islets 1 1 
Kidney 4 7 
Kidney + Islets 0 2 
Heart 1 1 
Total(n) 10 16 
Table 25.2. Incidence and severity of HVG reactions (re-I 
jection) in the bone marrow + whole organ trans-
plantation group. 
Organ n ACR Severity of ACR I 
Liver 5 
Liver + Islets 1 
Kidney 7 
Kidney + Islets 2 
Heart 1 
Total 16 
3 
1 
2 
2 
1 
9 
miidACR 
miidACR 
miidACR 
mild-moderate ACR 
Grade 0-3A 
Table 25.3. Percentage of donor cells in transplant re- i 
cipients (detected by flow cytometry). 
Control group (') 
Organs (X±SO) 
POO3 POO2S 
Liver 3.2±4.2 0.19±0.S 
Kidney 0.2±0.3 0 
Heart 0 0 
() Liver (n ~ 5\. Kidney (n ~ 4\. Heart (n - 1) 
1.'\ Liver (n ~ 21. Kidney (n ~ 2). Heart (n ~ 1) 
POD = Postoperative day. 
Study group (Z) 
(X±SO) 
POO3 POO28 
6.S± 1.5 12.8±2.3 I 
4.2::3.8 S.6±0.4 I 
7 3.6 
CD3-l+ Progenitor cells) in the recipient's blood up 
to b months after combined whole or~an/bone mar-
row transpl.1ntation. Interestingly, flow cytometry 
and PCR on the aspirated bone marrow of all 16 ca-
ses showed the presence of donor pro~enitor cells 6 
months ,1tter the combined transpl.mt. Quantitation 
of the chimerism also was done with the technique 
of PCR co-amplification developed by Trucco and his 
associates. In ,111 15 testable recipients the density of 
blood chimerism was 1000 fold or greater than that 
l)ccurring spontaneously [83, 84]. 
Post-operative immunologic monitoring was by 
mixed lymphocyte reaction (MLR) ,md cell mediated 
lympholysis (CML). 
In most of the patients who underwent whole or-
gan and bone marrow transplantation. the results of 
these tests showed a diminished donor specifiC reac-
tivity and full proliferation capacity ilnd cytotoxiC re-
sponse against third party lymphocytes for up to 5 
months after transplantation. 
Patients who had received allografts alone. on the 
other hand, remained responsive to both the donor 
and third party stimulators/effectors for up to 13 
months post-transplant. 
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These results indicate that donor bone marrow aug-
mentation enables us to reach a higher level of chime-
rism (macrochimerism) than after whole organ tran-
splantation alone (microchimerism). It is also clear 
that we can perform a donor bone marrow engraft-
ment without recourse to cytoablative conditioning of 
the recipient. This concept, by the way, has already 
been suggested by recent experimental findings. 
Thanks to its capacity to augment the degree of 
chimerism and reduce donor-specific reactivity, bo-
ne marrow augmentation can thus induce early im-
munomodulation in the host. 
For these reasons we can propose, for these pa-
tients, a reduction and/or early withdrawal of non-
specific immunosuppression. 
This clinical experience, however, has also shown 
that loss of donor specific non-reactivity in humans 
occurs with considerable variabilitv. 
This variability had already bee'n stressed in the 
series of Pittsburgh articles on chimerism. The result 
of mutual cell engagement may thus vary from clini-
cal stability without immunosuppressant drugs, to 
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stability dependent on immunosuppression, or to 
unstability (despite therapy), either in the form of re-
jection (most commonly). or GVHD (less common 
but most frequent with the liver, especially after bo-
ne marrow augmentation). 
The use of bone marrow augmentation in an or-
gan like the liver, which is in itself highly active in 
inducing cell chimerism, requires careful assessment 
of all the risks and benefits involved. In fact, we still 
don't know whether leukocyte augmentation will 
improve natural hepatic tolerogenicity and thereby 
facilitate the achievement of a drug-free state, or 
whether, on the contrary, it will increase the risk of 
GVHD. 
What is clear though, is that in all cases of bone 
marrow augmentation it should be mandatory to 
store autologous bone marrow for rescue therapy if 
GVHD occurs [.77]. 
Donor bone marrow will perhaps become an ex-
tremely flexible therapeutic resource in all organ or 
cell transplants for facilitating graft acceptance and 
inducing donor-specific non-reactivity. 
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